DF
MCID: DNG003
MIFTS: 59

Dengue Disease (DF)

Categories: Blood diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Dengue Disease

MalaCards integrated aliases for Dengue Disease:

Name: Dengue Disease 12 15 17
Dengue Fever 12 74 52 15 71
Dengue 54 42 43
Dengue Shock Syndrome 52 71
Philippine Hemorrhagic Fever 52
Singapore Hemorrhagic Fever 52
Dengue Hemorrhagic Fever 52
Dengue Virus Infection 52
Thai Hemorrhagic Fever 52
Hemorrhagic Dengue 52
Classical Dengue 12
Breakbone Fever 12
Classic Dengue 12
Severe Dengue 71
Df 52

Classifications:



External Ids:

Disease Ontology 12 DOID:12205
ICD9CM 34 061
MeSH 43 D003715
NCIt 49 C34528
SNOMED-CT 67 38362002
ICD10 32 A90
UMLS 71 C0011311 C0019100 C0376300

Summaries for Dengue Disease

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 99828 Definition Dengue fever (DF), caused by dengue virus , is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or DHF) and shock (dengue shock syndrome , or DSS). Epidemiology DF is found in the tropics worldwide, especially in Southeast Asia, the Pacific region, and the Americas, with 40% of the global population at risk. An estimated 50 to 100 million cases of DF, 500,000 hospitalizations, and 20,000 deaths occur yearly worldwide. Clinical description The vast majority of dengue virus infections result in DF, which is characterized by sudden onset of fever, malaise, headache (classically retro-orbital), and myalgia/arthralgia, often followed soon after by a petechial rash, which may be pruritic. In most cases, symptoms will resolve within 7 days without further complications. However, in a small minority of patients, a brief period of deffervescence is followed by worsening abdominal symptoms (pain, nausea, vomiting, diarrhea), thrombocytopenia , hemorrhage (DHF: epistaxis, bleeding gums, gastrointestinal bleeding) and a capillary leak syndrome (DSS: hemoconcentration, hypoalbuminemia, pleural effusion, shock). DHF/DSS are seen most often in children under the age of 15 years. Risk is greater with secondary heterologous infection by one of the four dengue virus serotypes, but severe disease may be seen with first infections. Etiology Over 25 different viruses cause viral hemorrhagic fever. Dengue virus belongs to the Flaviviridae family, genus Flavivirus. Four distinct serotypes, with significant strain variation, are recognized. Dengue viruses are maintained in humans and transmitted between them by the bite of infected mosquitoes, most commonly Aedes aegypti but also Aedes albopictus ). Person-to-person transmission has not been reported. Diagnostic methods Common diagnostic modalities include serologic testing by enzyme linked immunosorbent assay (ELISA) and reverse transcription polymerase chain reaction (RT-PCR). Virus isolation may also be performed in specialized laboratories. The viremic phase of DF/DHF is usually brief (first 3-5 days of illness), after which time detection of anti-dengue IgM antibodies , which appear as early as 2-4 days after disease onset, is the mainstay. Numerous commercial ELISA assays are available with varying degrees of sensitivity and specificity. Differential diagnosis DF is difficult to distinguish from a host of other febrile illnesses such as malaria and typhoid fever (see these terms), especially early in the course of disease before the rash appears. For DHF/DSS, other viral hemorrhagic fevers, leptospirosis, rickettsial infection (see these terms) and meningococcemia need to be excluded. Management and treatment As there is presently no antiviral drug available for DF/DHF, treatment is supportive, following the guidelines for treatment of severe septicemia. Insecticide-treated bed nets, room screens and elimination of larval development sites should be used in open-air settings to prevent further transmission. Prognosis Case-fatality rates for DF are less than 1% but may rise to as high as 40% in DHF/DSS, largely dependent upon whether access to advanced medical care exists. Children and persons with underlying chronic diseases such as diabetes, heart disease, and asthma are at increased risk. The most severe phase of disease usually lasts only a few days and survivors generally have no lasting sequelae. Visit the Orphanet disease page for more resources.

MalaCards based summary : Dengue Disease, also known as dengue fever, is related to dengue hemorrhagic fever and asymptomatic dengue, and has symptoms including fever and pruritus. An important gene associated with Dengue Disease is NEAT1 (Nuclear Paraspeckle Assembly Transcript 1), and among its related pathways/superpathways are Innate Immune System and Measles. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and t cells.

Disease Ontology : 12 A viral infectious disease that results in infection, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom fever, has symptom severe headache, has symptom severe pain behind the eyes, has symptom joint pain, has symptom muscle and bone pain, has symptom rash, and has symptom mild bleeding.

MedlinePlus : 42 Dengue is an infection caused by a virus. You can get it if an infected mosquito bites you. Dengue does not spread from person to person. It is common in warm, wet areas of the world. Outbreaks occur in the rainy season. Dengue is rare in the United States. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from your nose, gums, or under your skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. These forms of dengue are life-threatening. There is no specific treatment. Most people with dengue recover within 2 weeks. Until then, drinking lots of fluids, resting and taking non-aspirin fever-reducing medicines might help. People with the more severe forms of dengue usually need to go to the hospital and get fluids. To lower your risk when traveling to areas where dengue is found Wear insect repellent with DEET Wear clothes that cover your arms, legs and feet Close unscreened doors and windows

Wikipedia : 74 Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin... more...

Related Diseases for Dengue Disease

Diseases in the Dengue Virus family:

Dengue Disease

Diseases related to Dengue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 718)
# Related Disease Score Top Affiliating Genes
1 dengue hemorrhagic fever 33.1 IFNB1 CD40LG CD209
2 asymptomatic dengue 33.0 SENP8 CD40LG
3 dengue shock syndrome 32.8 SULT1A3 SENP8 IVNS1ABP CD40LG CD209
4 leptospirosis 31.4 PIK3C2A ICAM1 CD40LG
5 vaccinia 31.1 RNASEL IFNB1 ICAM1 CCL4
6 vasculitis 31.0 VCAM1 SULT1A3 MBL2 ICAM1 CD40LG
7 zika fever 31.0 SENP8 CD40LG CD209
8 murray valley encephalitis 30.9 SENP8 CD40LG
9 glomerulonephritis 30.8 VCAM1 MBL2 ICAM1 CD40LG
10 severe acute respiratory syndrome 30.8 MBL2 IFNB1 CD40LG CD209 CCL5
11 st. louis encephalitis 30.8 SENP8 CD40LG
12 proteasome-associated autoinflammatory syndrome 1 30.8 VCAM1 ICAM1 CCL5
13 q fever 30.8 MBL2 CD40LG CCL5
14 tick-borne encephalitis 30.8 IVNS1ABP IFNB1 CD209
15 alkhurma hemorrhagic fever 30.8 PIK3C2A MBL2 CD40LG
16 measles 30.8 IFNB1 CD40LG CD209 CCL5
17 autoimmune disease 30.7 VCAM1 MBL2 IFNB1 CD40LG CCL5
18 viral encephalitis 30.7 VCAM1 IFNB1 CD40LG CCL5
19 dermatitis, atopic 30.7 VCAM1 ICAM1 FCGR1A CCL5 CCL4
20 myocarditis 30.7 VCAM1 PIK3C2A ICAM1 CD40LG
21 kyasanur forest disease 30.6 SENP8 CD40LG
22 acquired immunodeficiency syndrome 30.6 VCAM1 NEAT1 ICAM1 CD40LG
23 aspergillosis 30.6 MBL2 CD209 CCL5
24 plasmodium vivax malaria 30.6 VCAM1 ICAM1 CD40LG
25 thrombocytopenic purpura, autoimmune 30.6 THPO IL11 CD40LG
26 newcastle disease 30.6 IVNS1ABP IFNB1 IFI27
27 ebola hemorrhagic fever 30.5 IFNB1 CD40LG CCL4
28 west nile fever 30.5 RNASEL CD40LG CD209
29 sickle cell anemia 30.5 VCAM1 ICAM1 CD40LG
30 herpes simplex 30.5 RNASEL IFNB1 HCFC1 CD209 CCL5
31 retinal vasculitis 30.5 IFNB1 CD40LG CCL4
32 antiphospholipid syndrome 30.5 VCAM1 SULT1A3 CD40LG
33 bronchiolitis 30.5 IL11 CD40LG CCL5
34 neutropenia 30.5 THPO MBL2 IL11 CD40LG
35 exanthem 30.5 SENP8 PIK3C2A CD40LG
36 la crosse encephalitis 30.5 RNASEL CD40LG
37 japanese encephalitis 30.4 IVNS1ABP IFNB1 CD209 CCL5
38 acute disseminated encephalomyelitis 30.4 IFNB1 CD40LG CCL4
39 plasmodium falciparum malaria 30.4 ICAM1 CD40LG CCL4
40 endocarditis 30.4 VCAM1 PIK3C2A CCL4
41 west nile encephalitis 30.4 RNASEL CD40LG
42 human immunodeficiency virus infectious disease 30.4 MBL2 CD209 CCL5 CCL4
43 peritonitis 30.4 VCAM1 ICAM1 FCGR1A CCL5
44 acalculous cholecystitis 30.4 SENP8 CD40LG
45 meningitis 30.3 MBL2 ICAM1 CD40LG CCL5 CCL4
46 acute hemorrhagic encephalitis 30.3 SENP8 ICAM1 CD40LG
47 trypanosomiasis 30.2 VCAM1 ICAM1 CCL5
48 crescentic glomerulonephritis 30.2 VCAM1 ICAM1 CCL4
49 yellow fever 30.2 SENP8 IFNB1 CCL5
50 otitis media 30.2 MBL2 ICAM1 CD40LG CCL5 CCL4

Graphical network of the top 20 diseases related to Dengue Disease:



Diseases related to Dengue Disease

Symptoms & Phenotypes for Dengue Disease

UMLS symptoms related to Dengue Disease:


fever, pruritus

Drugs & Therapeutics for Dengue Disease

Drugs for Dengue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
3
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
4
Hydroxychloroquine Approved Phase 4 118-42-3 3652
5 Anti-Allergic Agents Phase 4
6 Histamine Antagonists Phase 4
7 Histamine H1 Antagonists Phase 4
8
Histamine Phosphate Phase 4 51-74-1 65513
9 Neurotransmitter Agents Phase 4
10 Antiparasitic Agents Phase 4
11 Anti-Infective Agents Phase 4
12 Chloroquine diphosphate Phase 4 50-63-5
13 Amebicides Phase 4
14 Antiprotozoal Agents Phase 4
15 Antirheumatic Agents Phase 4
16 Antimalarials Phase 4
17 Analgesics, Non-Narcotic Phase 4
18 Analgesics Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Anthelmintics Phase 4
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4
22
tannic acid Approved Phase 3 1401-55-4
23
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
24
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 6474909
25
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
26
Nitazoxanide Approved, Investigational, Vet_approved Phase 2, Phase 3 55981-09-4 41684
27 Insect Repellents Phase 3
28 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
29 Protective Agents Phase 3
30 Anti-Bacterial Agents Phase 3
31 Antioxidants Phase 3
32 silymarin Phase 3
33
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
34
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
35
Ribavirin Approved Phase 2 36791-04-5 37542
36
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
37
Phenol Approved, Experimental Phase 2 108-95-2 996
38
Streptomycin Approved, Vet_approved Phase 2 57-92-1 19649
39
Metformin Approved Phase 1, Phase 2 657-24-9 14219 4091
40
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538
41
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 444795 5538
42 Hydrocortisone 17-butyrate 21-propionate Phase 2
43 Hydrocortisone hemisuccinate Phase 2
44 Rho(D) Immune Globulin Phase 2
45 Immunoglobulins, Intravenous Phase 2
46 gamma-Globulins Phase 2
47 Hemostatics Phase 2
48 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
49 Plasma-lyte 148 Phase 2
50 Immunologic Factors Phase 2

Interventional clinical trials:

(show top 50) (show all 244)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome Recruiting NCT04341493 Phase 4 Nitazoxanide 500 MG;Hydroxychloroquine
3 An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19 Terminated NCT04362332 Phase 4 Chloroquine Sulfate;Hydroxychloroquine
4 The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
5 A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
6 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets Against Malaria, JE & Dengue in Rural Communities in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
7 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
8 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT01374516 Phase 3
9 Lot-to-Lot Consistency and Bridging Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
10 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines Completed NCT02992418 Phase 3
11 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia Completed NCT02993757 Phase 3
12 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico Completed NCT02979535 Phase 3
13 Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
14 Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru Completed NCT01436396 Phase 3
15 Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico Completed NCT01411241 Phase 3
16 An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03771963 Phase 3
17 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue Completed NCT03423173 Phase 3
18 The Clinical Efficacy and Safety of a Proprietary Solution Containing Hypertonic Sodium Lactate (Totilac®) Infusion for Resuscitation of Patients With Hemorrhagic Shock Due to Multiple Injuries Completed NCT01433276 Phase 3 Hyperosmolar sodium lactate;Ringer's lactate
19 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic Area(s) for Dengue Completed NCT03341637 Phase 3
20 A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies) Completed NCT03342898 Phase 3
21 A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) Vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Country(Ies) for Dengue Completed NCT03525119 Phase 3
22 Albumin 5% as Resuscitation in Adult Dengue Fever Patients With Plasma Leakage Recruiting NCT04076254 Phase 3 Albumins;Fluid
23 A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue Recruiting NCT03999996 Phase 3
24 Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial Recruiting NCT04391127 Phase 3 Hydroxychloroquine;Ivermectin;Placebo
25 Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study Recruiting NCT03037164 Phase 3
26 Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old Active, not recruiting NCT02747927 Phase 3 TDV Placebo
27 Phase III Trial to Evaluate Efficacy and Safety of a Dengue 1,2,3,4 (Attenuated) Vaccine Active, not recruiting NCT02406729 Phase 3
28 A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular Recombinant 9-Valent Human Papillomavirus (9vHPV) Vaccine in Subjects Aged ≥9 to <15 Years in an Endemic Country for Dengue Not yet recruiting NCT04313244 Phase 3
29 Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria: Prospective, Multicenter, Randomized, Double-blind Study Not yet recruiting NCT04371952 Phase 3 Doxycycline;Placebo
30 Trial of Silymarin in Adults With COVID-19 Pneumonia Not yet recruiting NCT04394208 Phase 3 Silymarin;Placebo
31 Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope Not yet recruiting NCT04360356 Phase 2, Phase 3
32 The Effect of Chloroquine in the Treatment of Patients With Dengue Unknown status NCT00849602 Phase 1, Phase 2 Placebo;Chloroquine
33 Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
34 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years Previously Vaccinated Against Yellow Fever in Peru Completed NCT00788151 Phase 2
35 Immunogenicity and Safety of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam Completed NCT00875524 Phase 2
36 Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Previously Immunised With an Investigational Dengue or Yellow Fever Vaccine Completed NCT00730288 Phase 2
37 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed NCT00993447 Phase 2
38 Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naïve Adults Aged 18 to 45 Years Completed NCT00740155 Phase 2
39 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
40 Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore Completed NCT00880893 Phase 2
41 Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
42 Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India. Completed NCT01550289 Phase 2
43 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore Completed NCT02824198 Phase 2
44 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America Completed NCT02623725 Phase 2
45 Evaluation of the Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Administered With or Without Yellow Fever Vaccine in US Adults. Completed NCT01488890 Phase 2
46 Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand Completed NCT00842530 Phase 2
47 Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in South America Completed NCT01187433 Phase 2
48 Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
49 Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children Completed NCT00468858 Phase 2
50 Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo

Search NIH Clinical Center for Dengue Disease

Cochrane evidence based reviews: dengue

Genetic Tests for Dengue Disease

Anatomical Context for Dengue Disease

MalaCards organs/tissues related to Dengue Disease:

40
Testes, Skin, T Cells, Liver, Endothelial, Bone, Heart

Publications for Dengue Disease

Articles related to Dengue Disease:

(show top 50) (show all 5189)
# Title Authors PMID Year
1
Evaluation of a tetravalent dengue vaccine by serostatus and serotype. 42
32197106 2020
2
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. 42
32197107 2020
3
Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. 42
32197105 2020
4
Cardiac tamponade in a patient with dengue fever and lupus nephritis: a case report. 54 61
20089524 2010
5
Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation. 54 61
19822367 2009
6
Early diagnosis of dengue virus infection by detection of dengue viral antigen in peripheral blood mononuclear cell. 54 61
19755928 2009
7
The relationship of interacting immunological components in dengue pathogenesis. 61 54
19941667 2009
8
Skin lesions in hospitalized cases of dengue Fever. 61 54
18940116 2008
9
Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum. 61 54
18714359 2008
10
Analysis of antibody response in human dengue patients from the Mexican coast using recombinant antigens. 54 61
18279077 2008
11
Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. 54 61
17958746 2007
12
Characterization of dengue virus serotype 1 in epidemics in Porto Velho, Rondônia, in 2001-2003. 54 61
17653458 2007
13
The distribution of DEN infected people in Dushan and Xingyi area of Yunnan-Guizhou Plateau, China. 61 54
17257502 2006
14
Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). 54 61
17005690 2006
15
Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. 61 54
17006283 2006
16
DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus. 61 54
16140430 2006
17
An outbreak of dengue fever in periurban slums of Chandigarh, India, with special reference to entomological and climatic factors. 61 54
16385170 2005
18
[A variant in the CD209 (DC-SIGN) promoter is associated with severity of dengue disease]. 54 61
16274635 2005
19
Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. 54 61
16103156 2005
20
Optimized diagnosis of acute dengue fever in Swedish travelers by a combination of reverse transcription-PCR and immunoglobulin M detection. 61 54
15956408 2005
21
Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. 54 61
15498040 2004
22
Field- and laboratory-based active dengue surveillance in Chennai, Tamil Nadu, India: observations before and during the 2001 dengue epidemic. 54 61
15525913 2004
23
IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. 54 61
15122797 2004
24
Dengue fever mimicking plasma cell leukemia. 54 61
12873179 2003
25
Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. 54 61
12436482 2003
26
High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. 61 54
12355369 2002
27
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. 61 54
11724841 2001
28
Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. 61 54
11504411 2001
29
Cytotoxic factor-autoantibodies: possible role in the pathogenesis of dengue haemorrhagic fever. 54 61
11335136 2001
30
Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. 54 61
10928995 2000
31
Infection of five human liver cell lines by dengue-2 virus. 61 54
10686026 2000
32
An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients. 61 54
10698995 2000
33
Comparison of PanBio dengue duo enzyme-linked immunosorbent assay (ELISA) and MRL dengue fever virus immunoglobulin M capture ELISA for diagnosis of dengue virus infections in Southeast Asia. 54 61
10473522 1999
34
Status of antioxidants and other biochemical abnormalities in children with dengue fever. 61 54
10191585 1999
35
Production of cytotoxic factor by peripheral blood mononuclear cells (PBMC) in patients with dengue haemorrhagic fever. 54 61
9649218 1998
36
Immunoglobulin A-specific capture enzyme-linked immunosorbent assay for diagnosis of dengue fever. 54 61
9574674 1998
37
Detection of flaviviruses by reverse transcriptase-polymerase chain reaction with the universal primer set. 54 61
9130232 1997
38
Dengue. Muscle biopsy findings in 15 patients. 54 61
8274073 1993
39
Study of anti-dengue NS1 antibody by western blot. 54 61
2149144 1990
40
Local actions to health risks of heatwaves and dengue fever under climate change: Strategies and barriers among primary healthcare professionals in southern China. 61
32474308 2020
41
Comprehensive treatment in severe dengue during preterm and term labor: could tocolysis be useful? 61
30626246 2020
42
The V1016G mutation of the voltage-gated sodium channel (VGSC) gene contributes to the insecticide resistance of Aedes aegypti from Makassar, Indonesia. 61
32458116 2020
43
Coherence of dengue incidence and climate in the wet and dry zones of Sri Lanka. 61
32408457 2020
44
The old pharmaceutical oleoresin labdanum of Cistus creticus L. exerts pronounced in vitro anti-dengue virus activity. 61
31669444 2020
45
Dermatoses in international travellers seen at Bordeaux teaching hospital travel clinic, 2015-2018: a GeoSentinel-based study. 61
31916616 2020
46
Multiple dengue virus serotypes resistant transgenic Aedes aegypti fitness evaluated under laboratory conditions. 61
32138589 2020
47
Effects of natural and socioeconomic factors on dengue transmission in two cities of China from 2006 to 2017. 61
32408449 2020
48
Identification of potential inhibitors for targets involved in Dengue fever. 61
32552652 2020
49
Roles of Macrophage Migration Inhibitory Factor in Dengue Pathogenesis: From Pathogenic Factor to Therapeutic Target. 61
32545679 2020
50
Climatological, virological and sociological drivers of current and projected dengue fever outbreak dynamics in Sri Lanka. 61
32486949 2020

Variations for Dengue Disease

Expression for Dengue Disease

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Disease patients vs. healthy controls: 35 (show top 50) (show all 93)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 4.85 0.000
2 RRM2 ribonucleotide reductase M2 Blood + 4.48 0.000
3 CEP55 centrosomal protein 55kDa Blood + 4.33 0.000
4 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.30 0.000
5 XIST X inactive specific transcript (non-protein coding) Blood - 4.25 0.009
6 CD38 CD38 molecule Blood + 4.23 0.000
7 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 Blood + 4.10 0.000
8 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.08 0.000
9 IGHM immunoglobulin heavy constant mu Blood + 4.04 0.000
10 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.99 0.000
11 SHCBP1 SHC SH2-domain binding protein 1 Blood + 3.97 0.000
12 PBK PDZ binding kinase Blood + 3.97 0.000
13 TYMS thymidylate synthetase Blood + 3.96 0.000
14 PI3 peptidase inhibitor 3, skin-derived Blood - 3.93 0.000
15 CDCA2 cell division cycle associated 2 Blood + 3.91 0.000
16 SESN3 sestrin 3 Blood - 3.90 0.000
17 HMMR hyaluronan-mediated motility receptor (RHAMM) Blood + 3.83 0.000
18 MKI67 marker of proliferation Ki-67 Blood + 3.83 0.000
19 ZWINT ZW10 interacting kinetochore protein Blood + 3.83 0.000
20 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) Blood + 3.80 0.000
21 CDK1 cyclin-dependent kinase 1 Blood + 3.78 0.000
22 NCAPG non-SMC condensin I complex, subunit G Blood + 3.76 0.000
23 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.76 0.000
24 SPC25 SPC25, NDC80 kinetochore complex component Blood + 3.75 0.000
25 CDC20 cell division cycle 20 Blood + 3.73 0.000
26 CNTNAP3 contactin associated protein-like 3 Blood - 3.72 0.000
27 TOP2A topoisomerase (DNA) II alpha Blood + 3.71 0.000
28 NOV nephroblastoma overexpressed Blood - 3.71 0.000
29 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood + 3.69 0.015
30 CCNB2 cyclin B2 Blood + 3.62 0.000
31 CDKN3 cyclin-dependent kinase inhibitor 3 Blood + 3.62 0.000
32 KIAA0101 KIAA0101 Blood + 3.61 0.000
33 KIF2C kinesin family member 2C Blood + 3.60 0.000
34 TK1 thymidine kinase 1, soluble Blood + 3.59 0.000
35 RPS4Y1 ribosomal protein S4, Y-linked 1 Blood + 3.57 0.017
36 TTK TTK protein kinase Blood + 3.56 0.000
37 CDC6 cell division cycle 6 Blood + 3.56 0.000
38 CAV1 caveolin 1, caveolae protein, 22kDa Blood + 3.56 0.000
39 CENPA centromere protein A Blood + 3.54 0.000
40 CYAT1 immunoglobulin lambda light chain-like Blood + 3.52 0.000
41 ASPM abnormal spindle microtubule assembly Blood + 3.52 0.000
42 OR2W3 olfactory receptor, family 2, subfamily W, member 3 Blood - 3.51 0.000
43 UHRF1 ubiquitin-like with PHD and ring finger domains 1 Blood + 3.50 0.000
44 SELENBP1 selenium binding protein 1 Blood - 3.50 0.000
45 GINS2 GINS complex subunit 2 (Psf2 homolog) Blood + 3.49 0.000
46 MELK maternal embryonic leucine zipper kinase Blood + 3.47 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.47 0.000
48 CHEK1 checkpoint kinase 1 Blood + 3.46 0.000
49 CCNB1 cyclin B1 Blood + 3.45 0.000
50 KIF11 kinesin family member 11 Blood + 3.42 0.000
Search GEO for disease gene expression data for Dengue Disease.

Pathways for Dengue Disease

Pathways related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.56 VCAM1 RNASEL MIR3614 MBL2 IL11 IFNB1
2
Show member pathways
12.58 RNASEL IFNB1 ICAM1 CD209 CCL5
3
Show member pathways
12.47 VCAM1 RNASEL MIR3614 IL11 IFNB1 IFI27
4
Show member pathways
12.36 MIR3614 IFNB1 CCL5 CCL4
5
Show member pathways
11.99 VCAM1 RNASEL MIR3614 IFNB1 IFI27 ICAM1
6 11.8 VCAM1 ICAM1 FCGR1A CD40LG
7 11.71 THPO IL11 FCGR1A
8 11.68 MBL2 ICAM1 FCGR1A
9 11.67 VCAM1 IFNB1 ICAM1 CCL5
10 11.64 IL11 ICAM1 CCL5
11 11.57 VCAM1 ICAM1 CD40LG CCL4
12
Show member pathways
11.43 VCAM1 ICAM1 CD40LG
13 11.31 VCAM1 ICAM1 CD40LG
14 11.27 ICAM1 CCL5 CCL4
15 10.81 THPO IL11 CD40LG CCL5 CCL4
16 10.75 VCAM1 ICAM1

GO Terms for Dengue Disease

Cellular components related to Dengue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 VCAM1 THPO MBL2 IL11 IFNB1 ICAM1

Biological processes related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.96 IVNS1ABP IFI27 ICAM1 HCFC1 CD209
2 regulation of immune response GO:0050776 9.83 VCAM1 ICAM1 FCGR1A CD40LG
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 THPO ICAM1 CCL5 CCL4
4 cellular response to interferon-gamma GO:0071346 9.74 ICAM1 CCL5 CCL4
5 cellular response to interleukin-1 GO:0071347 9.71 ICAM1 CCL5 CCL4
6 interferon-gamma-mediated signaling pathway GO:0060333 9.69 VCAM1 ICAM1 FCGR1A
7 type I interferon signaling pathway GO:0060337 9.65 RNASEL IFNB1 IFI27
8 response to virus GO:0009615 9.62 IVNS1ABP IFNB1 CCL5 CCL4
9 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.61 VCAM1 ICAM1 CD209
10 B cell differentiation GO:0030183 9.56 VCAM1 IL11 IFNB1 CD40LG
11 negative regulation by host of viral transcription GO:0043922 9.55 CCL5 CCL4
12 negative regulation of viral genome replication GO:0045071 9.54 RNASEL IFNB1 CCL5
13 positive regulation of natural killer cell chemotaxis GO:2000503 9.46 CCL5 CCL4
14 positive regulation of T cell proliferation GO:0042102 9.46 VCAM1 CD40LG CD209 CCL5
15 cytokine-mediated signaling pathway GO:0019221 9.43 VCAM1 IL11 IFNB1 ICAM1 CCL5 CCL4
16 membrane to membrane docking GO:0022614 9.4 VCAM1 ICAM1
17 leukocyte cell-cell adhesion GO:0007159 9.02 VCAM1 ICAM1 CD40LG CD209 CCL5

Molecular functions related to Dengue Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR5 chemokine receptor binding GO:0031730 9.16 CCL5 CCL4
2 cytokine activity GO:0005125 9.1 THPO IL11 IFNB1 CD40LG CCL5 CCL4
3 CCR1 chemokine receptor binding GO:0031726 8.96 CCL5 CCL4

Sources for Dengue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....